spironolactone has been researched along with Respiratory Distress Syndrome in 4 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
Respiratory Distress Syndrome: A syndrome characterized by progressive life-threatening RESPIRATORY INSUFFICIENCY in the absence of known LUNG DISEASES, usually following a systemic insult such as surgery or major TRAUMA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study aimed to test the feasibility of spironolactone treatment in comparison with a surfactant in the early stage of acute respiratory distress syndrome (ARDS) in rats, as assessed by the acute lung injury (ALI) score, blood gas, brain natriuretic peptide (BNP) and N-terminal pro-brain natriuretic peptide (NT-proBNP)." | 7.76 | The efficacy of spironolactone in the treatment of acute respiratory distress syndrome-induced rats. ( Atalay, C; Aykan, S; Dogan, N; Gundogdu, C; Keles, MS, 2010) |
| "This study aimed to test the feasibility of spironolactone treatment in comparison with a surfactant in the early stage of acute respiratory distress syndrome (ARDS) in rats, as assessed by the acute lung injury (ALI) score, blood gas, brain natriuretic peptide (BNP) and N-terminal pro-brain natriuretic peptide (NT-proBNP)." | 3.76 | The efficacy of spironolactone in the treatment of acute respiratory distress syndrome-induced rats. ( Atalay, C; Aykan, S; Dogan, N; Gundogdu, C; Keles, MS, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cadegiani, FA | 1 |
| Edwards, C | 1 |
| Autret-Leca, E | 1 |
| Atalay, C | 1 |
| Dogan, N | 1 |
| Aykan, S | 1 |
| Gundogdu, C | 1 |
| Keles, MS | 1 |
4 other studies available for spironolactone and Respiratory Distress Syndrome
| Article | Year |
|---|---|
Can spironolactone be used to prevent COVID-19-induced acute respiratory distress syndrome in patients with hypertension?
Topics: Angiotensin-Converting Enzyme 2; Angiotensin-Converting Enzyme Inhibitors; Betacoronavirus; Coronavi | 2020 |
New Horizons: Does Mineralocorticoid Receptor Activation by Cortisol Cause ATP Release and COVID-19 Complications?
Topics: Adenosine Triphosphate; Angiotensin-Converting Enzyme 2; Blood Coagulation Disorders; COVID-19; COVI | 2021 |
[Drugs news].
Topics: Acetaminophen; Acupuncture; Asthma; Child; Glucocorticoids; Hemorrhage; Humans; Placebo Effect; Resp | 2009 |
The efficacy of spironolactone in the treatment of acute respiratory distress syndrome-induced rats.
Topics: Acute Lung Injury; Animals; Blood Gas Analysis; Disease Models, Animal; Lung; Male; Mineralocorticoi | 2010 |